Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.63 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385261 | 0.87 | CYP19A1 (0.60) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL14769100 | 0.83 | CYP19A1 (0.73) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1041969 | 0.79 | CYP19A1 (0.76) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL9524112 | 0.78 | CYP19A1 (0.59) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL10431406 | 0.78 | CYP11B2 (0.60) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL9524269 | 0.78 | CYP19A1 (0.49) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2142550 | 0.77 | CYP19A1 (0.74) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1041273 | 0.77 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1912921 | 0.77 | CYP19A1 (0.74) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2354499 | 0.77 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2091074-A | — | — | None | — | — | JP | disclosed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-7846957-B2 | Aromatase inhibition to enhance assisted reproduction | ARES TRADING S.A. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| EP-1898923-A4 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | CASPER ROBERT F (CA) | 2009-05-20 | — | — | EP | disclosed |
| EP-1804805-A4 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | UNIV WAYNE STATE (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1898923-A1 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | Casper, Robert F. (CA) | 2008-03-19 | — | — | EP | disclosed |
| US-20040235804-A1 | Inducing ovulation in a female suffering from anovulatory infertility by administering two or more daily doses of at least one aromatase inhibitor | ARES TRADING S.A. (CH) | 2004-11-25 | — | — | US | disclosed |
| US-20040204393-A1 | use of aromatase inhibitor in production of medicament for improving implantation and pregnancy rates for female undergoing assisted reproduction treatment comprising daily doses of aromatase inhibitor for administration during assisted reproduction or ovarian stimulation cycles to reduce serum estradiol | ARES TRADING S.A. (CH) | 2004-10-14 | — | — | US | disclosed |
| US-20040171660-A1 | Single dose aromatase inhibitor for treating infertility | ARES TRADINS S.A. (CH) | 2004-09-02 | — | — | US | disclosed |
| WO-2003082254-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AROMATASE INHIBITOR AND AN ESTROGEN SUITABLE FOR HORMONE REPLACEMENT THERAPY FOR A MALE | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082336-A1 | FEMALE BIRTH CONTROL METHOD | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082299-A1 | IMPROVED HORMONE REPLACEMENT THERAPY | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0356673-B1 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyridines and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1993-05-19 | — | — | EP | disclosed |
| JP-H0291074-A | SUBSTITUTED 5,6,7,8-TETRAHYDROIMIDAZO(1,5-A)PYRIDINE AND ITS PRODUCTION | FARMITALIA CARLO ERBA SPA | 1990-03-30 | — | — | JP | disclosed |
| EP-0356673-A2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyridines and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235804-A1 | Inducing ovulation in a female suffering from anovulatory infertility by administering two or more daily doses of at least one aromatase inhibitor | CYP19A1, FSHR, GNRHR | CYP19A1 1/4885CYP11B2 31/4885CYP11B1 27/4885 |
| US-20040204393-A1 | use of aromatase inhibitor in production of medicament for improving implantation and pregnancy rates for female undergoing assisted reproduction treatment comprising daily doses of aromatase inhibitor for administration during assisted reproduction or ovarian stimulation cycles to reduce serum estradiol | CYP19A1, CYP11A1, HSD17B11 | CYP19A1 1/4885CYP11B2 47/4885CYP11B1 36/4885 |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | CYP19A1 1/4885CYP11B2 25/4885CYP11B1 20/4885 |
| US-20040171660-A1 | Single dose aromatase inhibitor for treating infertility | CYP19A1, FSHR, SHBG | CYP19A1 1/4885CYP11B2 99/4885CYP11B1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.